Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1251 - 1258 of 1258

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1501 - 1525 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Lartruvo for Advanced Soft Tissue Sarcoma – Details	pcodr_profund_olaratumab_lartruvo_sts.pdf pcodr_olaratumab_lartruvo_sts_fn_rec.pdf pcodr_olaratumab_lartruvo_sts_fn_cgr.pdf pcodr_olaratumab_lartruvo_sts_fn_egr.pdf pcodr_olaratumab_lartruvo_sts_in_rec.pdf pcodr_olaratumab_lartruvo_sts_pagfdk.pdf pcodr_olaratumab_lartruvo_sts_fdk_elc.pdf pcodr_olaratumab_lartruvo_sts_clnfdk.pdf pcodr_olaratumab_lartruvo_sts_coi_pt.pdf pcodr_olaratumab_lartruvo_sts_coi_cln.pdf	May 3, 2018	Reimbursement Review		Complete	PC0111-000
tenofovir alafenamide	SR0537_Vemlidy_complete_Mar-28-18.pdf SR0537_Vemlidy_CL_Report.pdf SR0537_Vemlidy_PE_Report.pdf SR0537_Vemlidy_PI_Submissions.pdf	Apr 30, 2018	Reimbursement Review		Complete	SR0537-000
tocilizumab	SR0534_Actemra_GCA_complete_Mar-27-18.pdf SR0534_ActemraGCA_CL_Report.pdf SR0534_Actemra_GCA_PE_Report.pdf SR0534_Actemra_GCA_PI_Submissions.pdf	Apr 30, 2018	Reimbursement Review		Complete	SR0534-000
Erbitux for Left Sided Metastatic Colorectal Cancer – Details		Apr 26, 2018	Reimbursement Review		Cancelled	PC0128-000
Drugs for the Management of Rheumatoid Arthritis		Apr 25, 2018	Health Technology Review	Health Technology Assessment	Completed	HT0010-000
Apomorphine	SR0527_Movapo_complete-Jan-25-18.pdf SR0527_Movapo_CL_Report.pdf SR0527_Movapo_PE_Report.pdf SR0527_Movapo_Patient_Input.pdf	Apr 18, 2018	Reimbursement Review		Complete	SR0527-000
Use of Real-World Evidence in Single-Drug Assessments Environmental Scan		Apr 18, 2018	Health Technology Review	Environmental Scan	Completed	ES0323-000
Vectibix for Left Sided Metastatic Colorectal Cancer – Details	pcodr_profund_panitumumab_vectibix_ls_mcrc.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_cgr.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_egr .pdf pcodr_panitumumab_vectibix_ls_mcrc_in_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_pagfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_fdk_amgen.pdf pcodr_panitumumab_vectibix_ls_mcrc_ptfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_clnfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_pt.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_cln.pdf	Apr 16, 2018	Reimbursement Review		Complete	PC0118-000
Alecensaro for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (second line) – Details	AlectinibAlecensaro_NSCLCsecondline10114ProvFunding.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_cgr .pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_2ln_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_cln.pdf	Apr 16, 2018	Reimbursement Review		Complete	PC0114-000
glecaprevir pibrentasvir	SR0523_Maviret_complete-Jan-25-18.pdf SR0523_Maviret_CL_Report.pdf SR0523_Maviret_PE_Report.pdf SR0523_Maviret_Patient_Input.pdf	Apr 12, 2018	Reimbursement Review		Complete	SR0523-000
Bavencio for metastatic Merkel Cell Carcinoma – Details	AvelumabBavencio_metastaticMerkelcellcarcinoma10124_ProvFunding2019-11-19.pdf pcodr_avelumab_bavencio_mcc_fn_rec.pdf pcodr_avelumab_bavencio_mcc_fn_cgr.pdf pcodr_avelumab_bavencio_mcc_fn_egr.pdf pcodr_avelumab_bavencio_mmcc_in_rec.pdf pcodr_avelumab_bavencio_mcc_pagfdk.pdf pcodr_avelumab_bavencio_mcc_espa.pdf pcodr_avelumab_bavencio_mcc_clnfdk.pdf pcodr_avelumab_bavencio_mcc_coi_pt.pdf pcodr_avelumab_bavencio_mcc_coi_cln.pdf	Apr 6, 2018	Reimbursement Review		Complete	PC0124-000
sofosbuvir velpatasvir voxilaprevir	SR0529_Vosevi_complete_Jan-25-18.pdf SR0529_Vosevi_CL_Report.pdf SR0529_Vosevi_PE_Report.pdf SR0529 Vosevi_Patient_Input.pdf	Apr 5, 2018	Reimbursement Review		Complete	SR0529-000
guselkumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0530_Tremfya_complete_Feb-23-18.pdf SR0530_Tremfya_CL_Report.pdf SR0530_Tremfya_PE_Report.pdf SR0530_Tremfya_PI_Submissions.pdf	Apr 5, 2018	Reimbursement Review		Complete	SR0530-000
Gene Therapy: International Regulatory and Health Technology Assessment (HTA) Activities and Reimbursement Status		Mar 28, 2018	Health Technology Review	Environmental Scan	Completed	ES0325-000
fluocinolone acetonide		Mar 26, 2018	Reimbursement Review		Withdrawn	SR0549-000
Keytruda for Metastatic Urothelial Carcinoma – Details	pcodr_provfund_pembrolizumab_keytruda_MUC.pdf pcodr_pembrolizumab_keytruda_muc_fn_rec.pdf pcodr_pembrolizumab_keytruda_muc_fn_cgr.pdf pcodr_pembrolizumab_keytruda_muc_fn_egr.pdf pcodr_pembrolizumab_keytruda_muc_in_rec.pdf pcodr_pembrolizumab_keytruda_muc_pagfdk.pdf pcodr_pembrolizumab_keytruda_muc_fdk_merck.pdf pcodr_pembrolizumab_keytruda_muc_clnfdk.pdf pcodr_pembrolizumab_keytruda_muc_coi_pt.pdf pcodr_pembrolizumab_keytruda_muc_coi_cln.pdf	Mar 19, 2018	Reimbursement Review		Complete	PC0117-000
Venclexta for Chronic Lymphocytic Leukemia – Details	pcodr_profund_venetoclax_venclexta_cll.pdf pcodr_venetoclax_venclexta_cll_fn_rec.pdf pcodr_venetoclax_venclexta_cll_fn_cgr.pdf pcodr_venetoclax_venclexta_cll_fn_egr.pdf pcodr_venetoclax_venclexta_cll_in_rec.pdf pcodr_venetoclax_venclexta_cll_pagfdk.pdf pcodr_venetoclax_venclexta_cll_fdk_abbvie.pdf pcodr_venetoclax_venclexta_cll_ptfdk.pdf pcodr_venetoclax_venclexta_cll_clnfdk.pdf pcodr_venetoclax_venclexta_cll_coi_pt.pdf pcodr_venetoclax_venclexta_cll_coi_cln.pdf	Mar 19, 2018	Reimbursement Review		Complete	PC0105-000
Adcetris for Hodgkin’s Lymphoma (post-ASCT) Resubmission – Details	pcodr_profund_brentuximab_adcetris_hl_post-asct_resub.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_rec.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_cgr.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_egr.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_in_rec.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_pagfdk.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fdk_sgi.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_clnfdk.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_pt.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_cln.pdf	Mar 8, 2018	Reimbursement Review		Complete	PC0116-000
migalastat	SR0522_Galafold_complete_Jan-26-18.pdf SR0522_Galafold_CL_Report.pdf SR0522_Galafold_PE_Report.pdf SR0522_Galafold_Patient_Input.pdf	Mar 1, 2018	Reimbursement Review		Complete	SR0522-000
ocrelizumab	SR0519_Ocrevus_RMS_complete_Nov-23-17.pdf SR0519_Ocrevus_RMS _PE_Report.pdf SR0519_Ocrevus_RMS_CL_Report.pdf SR0519_Ocrevus_RMS_PI_Submissions.pdf	Mar 1, 2018	Reimbursement Review		Complete	SR0519-000
lixisenatide	SR0520_Adlyxine_complete_Nov-23-17.pdf SR0520_Adlyxine_CL_Report.pdf SR0520_Adlyxine_PE_Report.pdf SR0520_Adlyxine_PI_Submissions.pdf	Mar 1, 2018	Reimbursement Review		Complete	SR0520-000
Faslodex for Locally Advanced or Metastatic Breast Cancer – Details	pcodr_provfund_fulvestrant_faslodex_mbc.pdf pcodr_fulvestrant_faslodex_mbc_fn_rec.pdf pcodr_fulvestrant_faslodex_mbc_fn_cgr.pdf pcodr_fulvestrant_faslodex_mbc_fn_egr.pdf pcodr_fulvestrant_faslodex_mbc_in_rec.pdf pcodr_fulvestrant_faslodex_mbc_pagfdk.pdf pcodr_fulvestrant_faslodex_mbc_fdk_asz.pdf pcodr_fulvestrant_faslodex_mbc_ptfdk.pdf pcodr_fulvestrant_faslodex_mbc_clnfdk.pdf pcodr_fulvestrant_faslodex_mbc_coi_pt.pdf pcodr_fulvestrant_faslodex_mbc_coi_cln.pdf	Feb 16, 2018	Reimbursement Review		Complete	PC0110-000
Drugs for Type 2 Diabetes: Second-Line Therapy Review Update		Feb 7, 2018	Health Technology Review	Therapeutic Review	Completed	TR0012-000
Cabozantinib for Advanced Renal Cell Carcinoma – Details		Jan 25, 2018	Reimbursement Review		Withdrawn	PC0123-000
insulin degludec	SR0521_Tresiba_complete_Nov-22-17_e.pdf SR0521_Tresiba_CL_Report.pdf SR0521_Tresiba_PE_Report.pdf SR0521_Tresiba_PI_Submissions.pdf	Jan 24, 2018	Reimbursement Review		Complete	SR0521-000